Our compounds
Research Pipeline
PSYCHIATRY
BIPOLAR DEPRESSION with SUICIDAL IDEATION
SPA, Breakthrough Therapy designation, Biomarker Letter of Support
Sequential Therapy for the Treatment of Severe Bipolar Depression.
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
RESPIRATORY / COVID-19 –
FRANCHISE UNDER EVALUATION
Fast Track
NIH ACTIV-3b (TESICO)
Study Completed
Study Sponsored by National Institute of Health | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Study Completed
Study Sponsored by National Institute of Health | ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Study Discontinued
Inhaled ZYESAMI® (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19
* This study has been paused while NRx evaluates whether to increase the sample size, change the trial endpoint / enrollment criteria or discontinue the study. A separate inhaled study that was being conducted by Quantum Leap Healthcare Collaborative (I-SPY) has been stopped.
** Data and rights held by Research Foundation for the State University of New York; NRx Pharmaceuticals has a license
Follow Us
Keep up with the latest news and updates about NRx through social media.